Moderna said it had secured $1.5 billion in financing to underpin operations as it pursues break‑even targets in 2028 and pivots investment toward an expanded seasonal vaccine franchise and opportunistic oncology and rare‑disease programs. The announcement followed company moves to wind down three clinical mRNA programs, part of a broader reshaping of the pipeline. Management framed the funding as strategic runway to prioritize higher‑return assets while cutting less promising initiatives. For industry observers: the move underscores biopharma tradeoffs between breadth of R&D and capital discipline in the mRNA era.